Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Revamps Commercial Ops, Prioritizes Fixed-Ratio Lantus-Lyxumia Combo

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi plans to split its commercial organization into two units as the French drug giant starts to emerge from its patent cliff with a return to growth and a renewed focus on new diabetes therapies.

Advertisement

Related Content

Novo Struggles In Japan, Sanofi Struggles With Distributors: Emerging Markets Earnings Roundup (Part 7)
On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel